UK-based Tenpoint Therapeutics Ltd revealed that the US FDA has issued an approval to Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% as the first and only dual-agent combination eye drop indicated to treat presbyopia in adults. Presbyopia is the age-related decline in near vision that typically begins around age 45 and affects an estimated 2 billion people worldwide, including about 128 million in the US.

Yuvezzi’s fixed-dose combination of a cholinergic agent (carbachol) and an alpha-adrenergic agonist (brimonidine tartrate) is designed to constrict the pupil and create a “pinhole effect,” improving near visual acuity and depth of focus with once-daily dosing. The approval follows positive results from two pivotal Phase III studies involving more than 800 participants, where the therapy achieved statistically significant improvements in near vision up to eight hours without compromising distance vision and demonstrated a favorable tolerability profile.

Yuvezzi is expected to become broadly commercially available in the US in the second quarter of 2026, representing Tenpoint’s first approved product and a potential catalyst for its broader vision-care franchise strategy.

Industry context

Presbyopia is a progressive, age-related condition characterized by the gradual loss of the eye’s ability to focus on near objects. It is caused primarily by the stiffening and loss of elasticity of the crystalline lens and changes in the ciliary muscle, which reduce the eye’s accommodative amplitude.

Recent years have seen a surge in pharmacologic innovation for the condition, with regulatory approvals in the US for single agent drugs Vuity (pilocarpine; AbbVie/Allergan, 2021), and Vizz (aceclidine; LENZ Therapeutics, 2025). As with Yuvezzi, these act as miotic agents, inducing pupil constriction to increase depth of focus. Yuvezzi’s combination of carbachol and brimonidine tartrate uses two complementary mechanisms, with carbachol constricting the pupil while brimonidine helps regulate iris muscle activity and may improve bioavailability and tolerability of the miotic effect, potentially with improved side-effects as a consequence.